The estimated Net Worth of Robert Scott Mc Dowell is at least $4.22 Milion dollars as of 6 January 2020. Robert Dowell owns over 2,650 units of MyoKardia stock worth over $1,210,691 and over the last 17 years he sold MYOK stock worth over $181,393. In addition, he makes $2,824,660 as Chief Scientific Officer at MyoKardia.
Sign up
Robert McDowell MYOK stock SEC Form 4 insiders trading
Robert has made over 2 trades of the MyoKardia stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 2,650 units of MYOK stock worth $181,393 on 6 January 2020.
The largest trade he's ever made was exercising 6,875 units of MyoKardia stock on 1 January 2020 worth over $1,546,256. On average, Robert trades about 595 units every 0 days since 2007. As of 6 January 2020 he still owns at least 5,383 units of MyoKardia stock.
You can see the complete history of Robert Dowell stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert McDowell biography
Dr. Robert Scott McDowell Ph.D. serves as Chief Scientific Officer of the Company. Dr. McDowell has served as our Chief Scientific Officer since October 2017, and prior to that as our Senior Vice President of Drug Discovery since July 2012. Prior to joining us, Dr. McDowell led drug discovery at 3-V Biosciences, Inc. from October 2008 to July 2012, advancing the company’s lead program into development. Prior to 3-V Biosciences, he served as vice president of research at Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, from January 2000 to 2008, where he oversaw drug discovery, translational research and manufacturing functions. Prior to Sunesis Pharmaceuticals, Dr. McDowell led the structural chemistry group at Axys Pharmaceuticals, Inc. Before joining Axys, Dr. McDowell was a senior scientist at Genentech Inc., where he developed successful strategies for peptidomimetic design. Dr. McDowell has authored more than 40 peer-reviewed manuscripts and is an inventor on more than 20 issued U.S. patents. Dr. McDowell holds a B.S. in chemistry and physics from Butler University and a Ph.D. in chemistry from the University of California, Berkeley.
What is the salary of Robert McDowell?
As the Chief Scientific Officer of MyoKardia, the total compensation of Robert McDowell at MyoKardia is $2,824,660. There are 2 executives at MyoKardia getting paid more, with Tassos Gianakakos having the highest compensation of $10,223,600.
How old is Robert McDowell?
Robert McDowell is 62, he's been the Chief Scientific Officer of MyoKardia since 2017. There are 4 older and 7 younger executives at MyoKardia. The oldest executive at MyoKardia, Inc. is Mary Cranston, 72, who is the Independent Director.
What's Robert McDowell's mailing address?
Robert's mailing address filed with the SEC is C/O MYOKARDIA, INC., 1000 SIERRA POINT PARKWAY, BRISBANE, CA, 94005.
Insiders trading at MyoKardia
Over the last 9 years, insiders at MyoKardia have traded over $313,807,381 worth of MyoKardia stock and bought 2,317,816 units worth $42,556,877 . The most active insiders traders include Sanofi, Kevin P Starr a Rock Ventures Ii, L.P.Third.... On average, MyoKardia executives and independent directors trade stock every 16 days with the average trade being worth of $21,462,936. The most recent stock trade was executed by Anastasios Gianakakos on 2 July 2020, trading 5,000 units of MYOK stock currently worth $469,900.
What does MyoKardia do?
MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA.
What does MyoKardia's logo look like?
Complete history of Robert Dowell stock trades at MyoKardia a Sunesis Pharmaceuticals Inc
MyoKardia executives and stock owners
MyoKardia executives and other stock owners filed with the SEC include:
-
Tassos Gianakakos,
President, Chief Executive Officer, Director -
William Fairey,
Executive Vice President and Chief Commercial Officer -
Robert McDowell,
Chief Scientific Officer -
Jake Bauer,
Chief Business Officer -
Taylor Harris,
Chief Financial Officer -
Mark Perry,
Non-Executive Independent Chairman of the Board -
Mary Cranston,
Independent Director -
Sunil Agarwal,
Independent Director -
Wendy Yarno,
Independent Director -
David Meeker,
Independent Director -
Kimberly Popovits,
Independent Director -
Michelle Corral,
IR Contact Officer -
Denelle Waynick,
General Counsel, Corporate Secretary -
Rock Ventures Ii, L.P.Third...,
-
Sanofi,
10% owner -
Eric Topol,
Director -
Anastasios Gianakakos,
President and CEO -
Joseph Lambing,
See Remarks -
Marc Semigran,
Chief Medical Officer -
Kevin P Starr,
Director -
Steven Chan,
See Remarks -
Charles J Homcy,
Director -
June Lee,
EVP, Chief Development Officer -
Jonathan C Fox,
Chief Medical Officer -
Rock Ventures Iii, L.P.Thir...,
-
Cynthia J Ladd,
General Counsel -
Rock Ventures Ii, L.P.Third...,